Fam-Trastuzumab Deruxtecan-nxki Doubles Progression-Free Survival in HER2-Low Metastatic Breast Cancer Click the link below to read more:...

DESTINY-Breast03: Should Trastuzumab Deruxtecan Be the Preferred Second-Line Regimen in HER2-Positive Metastatic Breast Cancer? Click the...